TABLE OF CONTENTS
1 INTRODUCTION 118
1.1 OBJECTIVES OF THE STUDY 118
1.2 MARKET DEFINITION 118
1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DIAGNOSTIC MARKET 118
1.4 CURRENCY AND PRICING 120
1.5 LIMITATIONS 120
1.6 MARKETS COVERED 120
2 MARKET SEGMENTATION 128
2.1 MARKETS COVERED 128
2.2 GEOGRAPHICAL SCOPE 129
2.3 YEARS CONSIDERED FOR THE STUDY 130
2.4 DBMR TRIPOD DATA VALIDATION MODEL 131
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.6 MULTIVARIATE MODELLING 135
2.7 MARKET APPLICATION COVERAGE GRID 136
2.8 INSTRUMENT BASED LIFELINE CURVE 137
2.9 DBMR MARKET POSITION GRID 138
2.10 VENDOR SHARE ANALYSIS 140
2.11 SECONDARY SOURCES 141
2.12 ASSUMPTIONS 141
3 EXECUTIVE SUMMARY 142
4 PREMIUM INSIGHTS 145
4.1 PESTEL ANALYSIS 146
4.2 PORTERS FIVE FORCES 147
4.3 PATENT ANALYSIS OF EUROPE UTERINE CANCER DIAGNOSTICS MARKET 148
4.4 REIMBURSEMENT SCENARIO 149
4.5 INDUSTRY INSIGHTS: 150
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 150
4.7 PRICING STRATEGIES 150
4.8 CONCLUSION 151
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 152
4.10 COST OF UTERINE CANCER PROCEDURE 154
5 REGULATORY FRAMEWORK 155
6 MARKET OVERVIEW 157
6.1 DRIVERS 159
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 159
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 159
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 160
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 160
6.2 RESTRAINTS 161
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 161
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 161
6.3 OPPORTUNITIES 162
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 162
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 162
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 163
6.4 CHALLENGES 163
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 163
6.4.2 HIGH COST OF IMAGING SYSTEMS 164
7 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 165
7.1 OVERVIEW 166
7.2 INSTRUMENT-BASED 169
7.2.1 ULTRASOUND SCANNING 170
7.2.1.1 SYSTEMS 170
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 171
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 171
7.2.1.4 ACCESSORIES 171
7.2.2 IMAGING DEVICES 171
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 172
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 172
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 172
7.2.2.4 OTHERS 172
7.2.3 TESTS 173
7.2.3.1 BLOOD TESTS 173
7.2.3.1.1 COMPLETE BLOOD COUNT 173
7.2.3.1.2 CA125 MARKER BLOOD TEST 173
7.2.3.2 URINE TESTS 174
7.2.3.3 OTHER TESTS 174
7.2.4 OTHERS 174
7.3 PROCEDURE BASED 174
7.3.1 ENDOMETRIAL BIOPSY 175
7.3.2 HYSTEROSCOPY 175
7.3.3 DILATION & CURETTAGE 175
7.3.4 CYSTOSCOPY 175
7.3.5 PROCTOSCOPY 176
7.3.6 OTHERS 176
8 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 177
8.1 OVERVIEW 178
8.2 ENDOMETRIAL CANCER 181
8.2.1 SEROUS ADENOCARCINOMA 182
8.2.1.1 INSTRUMENT-BASED 182
8.2.1.1.1 ULTRASOUND SCANNING 183
8.2.1.1.2 IMAGING DEVICES 183
8.2.1.1.3 TESTS 183
8.2.1.1.4 OTHERS 183
8.2.1.2 PROCEDURE-BASED 184
8.2.1.2.1 ENDOMETRIAL BIOPSY 184
8.2.1.2.2 HYSTEROSCOPY 184
8.2.1.2.3 DILATION & CURETTAGE 184
8.2.1.2.4 CYSTOSCOPY 184
8.2.1.2.5 PROCTOSCOPY 184
8.2.1.2.6 OTHERS 185
8.2.2 ADENOSQUAMOUS CARCINOMA 185
8.2.2.1 INSTRUMENT-BASED 185
8.2.2.1.1 ULTRASOUND SCANNING 185
8.2.2.1.2 IMAGING DEVICES 186
8.2.2.1.3 TESTS 186
8.2.2.1.4 OTHERS 186
8.2.2.2 PROCEDURE-BASED 186
8.2.2.2.1 ENDOMETRIAL BIOPSY 186
8.2.2.2.2 HYSTEROSCOPY 186
8.2.2.2.3 DILATION & CURETTAGE 187
8.2.2.2.4 CYSTOSCOPY 187
8.2.2.2.5 PROCTOSCOPY 187
8.2.2.2.6 OTHERS 187
8.2.3 UTERINE CARCINOSARCOMA 187
8.2.3.1 INSTRUMENT-BASED 187
8.2.3.1.1 ULTRASOUND SCANNING 188
8.2.3.1.2 IMAGING DEVICES 188
8.2.3.1.3 TESTS 188
8.2.3.1.4 OTHERS 188
8.2.3.2 PROCEDURE-BASED 189
8.2.3.2.1 ENDOMETRIAL BIOPSY 189
8.2.3.2.2 HYSTEROSCOPY 189
8.2.3.2.3 DILATION & CURETTAGE 189
8.2.3.2.4 CYSTOSCOPY 189
8.2.3.2.5 PROCTOSCOPY 189
8.2.3.2.6 OTHERS 190
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 190
8.2.4.1 INSTRUMENT-BASED 190
8.2.4.1.1 ULTRASOUND SCANNING 190
8.2.4.1.2 IMAGING DEVICES 191
8.2.4.1.3 TESTS 191
8.2.4.1.4 OTHERS 191
8.2.4.2 PROCEDURE-BASED 191
8.2.4.2.1 ENDOMETRIAL BIOPSY 191
8.2.4.2.2 HYSTEROSCOPY 191
8.2.4.2.3 DILATION & CURETTAGE 192
8.2.4.2.4 CYSTOSCOPY 192
8.2.4.2.5 PROCTOSCOPY 192
8.2.4.2.6 OTHERS 192
8.3 UTERINE SARCOMA 192
8.3.1 LEIOMYOSARCOMA 193
8.3.1.1 INSTRUMENT-BASED 193
8.3.1.1.1 ULTRASOUND SCANNING 194
8.3.1.1.2 IMAGING DEVICES 194
8.3.1.1.3 TESTS 194
8.3.1.1.4 OTHERS 194
8.3.1.2 PROCEDURE-BASED 195
8.3.1.2.1 ENDOMETRIAL BIOPSY 195
8.3.1.2.2 HYSTEROSCOPY 195
8.3.1.2.3 DILATION & CURETTAGE 195
8.3.1.2.4 CYSTOSCOPY 195
8.3.1.2.5 PROCTOSCOPY 195
8.3.1.2.6 OTHERS 196
8.3.2 ENDOMETRIAL STROMAL SARCOMA 196
8.3.2.1 INSTRUMENT-BASED 196
8.3.2.1.1 ULTRASOUND SCANNING 196
8.3.2.1.2 IMAGING DEVICES 197
8.3.2.1.3 TESTS 197
8.3.2.1.4 OTHERS 197
8.3.2.2 PROCEDURE-BASED 197
8.3.2.2.1 ENDOMETRIAL BIOPSY 197
8.3.2.2.2 HYSTEROSCOPY 197
8.3.2.2.3 DILATION & CURETTAGE 198
8.3.2.2.4 CYSTOSCOPY 198
8.3.2.2.5 PROCTOSCOPY 198
8.3.2.2.6 OTHERS 198
8.3.3 UNDIFFERENTIATED SARCOMA 198
8.3.3.1 INSTRUMENT-BASED 199
8.3.3.1.1 ULTRASOUND SCANNING 199
8.3.3.1.2 IMAGING DEVICES 199
8.3.3.1.3 TESTS 199
8.3.3.1.4 OTHERS 199
8.3.3.2 PROCEDURE-BASED 200
8.3.3.2.1 ENDOMETRIAL BIOPSY 200
8.3.3.2.2 HYSTEROSCOPY 200
8.3.3.2.3 DILATION & CURETTAGE 200
8.3.3.2.4 CYSTOSCOPY 200
8.3.3.2.5 PROCTOSCOPY 201
8.3.3.2.6 OTHERS 201
9 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 202
9.1 OVERVIEW 203
9.2 >60 YEARS 206
9.3 51-60 YEARS 207
9.4 41-50 YEARS 208
9.5 31-40 YEARS 209
9.6 <30 YEARS 210
10 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 211
10.1 OVERVIEW 212
10.2 HOSPITALS 215
10.3 DIAGNOSTIC CENTERS 216
10.4 CANCER RESEARCH CENTERS 217
10.5 AMBULATORY SURGICAL CENTERS 218
10.6 SPECIALIZED CLINICS 219
10.7 OTHERS 220
11 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 221
11.1 OVERVIEW 222
11.2 DIRECT TENDER 225
11.3 THIRD PARTY DISTRIBUTORS 226
11.4 OTHERS 227
12 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 228
12.1 EUROPE 229
12.1.1 GERMANY 245
12.1.2 FRANCE 256
12.1.3 UNITED KINGDOM 268
12.1.4 ITALY 281
12.1.5 SPAIN 293
12.1.6 RUSSIA 304
12.1.7 NETHERLANDS 317
12.1.8 POLAND 330
12.1.9 SWITZERLAND 343
12.1.10 BELGIUM 356
12.1.11 SWEDEN 369
12.1.12 NORWAY 382
12.1.13 DENMARK 395
12.1.14 FINLAND 408
12.1.15 TURKEY 421
12.1.16 REST OF EUROPE 434
13 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 435
13.1 COMPANY SHARE ANALYSIS: EUROPE 435
14 SWOT ANALYSIS 436
15 COMPANY PROFILE 437
15.1 KONINKLIJKE PHILIPS N.V. 437
15.1.1 COMPANY SNAPSHOT 437
15.1.2 REVENUE ANALYSIS 437
15.1.3 COMPANY SHARE ANALYSIS 438
15.1.4 PRODUCT PORTFOLIO 438
15.1.5 RECENT DEVELOPMENTS 438
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 440
15.2.1 COMPANY SNAPSHOT 440
15.2.2 COMPANY SHARE ANALYSIS 440
15.2.3 PRODUCT PORTFOLIO 441
15.2.4 RECENT DEVELOPMENTS 441
15.3 GENERAL ELECTRIC COMPANY 442
15.3.1 COMPANY SNAPSHOT 442
15.3.2 REVENUE ANALYSIS 442
15.3.3 COMPANY SHARE ANALYSIS 443
15.3.4 PRODUCT PORTFOLIO 443
15.3.5 RECENT DEVELOPMENTS 443
15.4 SIEMENS HEALTHCARE GMBH 445
15.4.1 COMPANY SNAPSHOT 445
15.4.2 REVENUE ANALYSIS 445
15.4.3 COMPANY SHARE ANALYSIS 446
15.4.4 PRODUCT PORTFOLIO 446
15.4.5 RECENT DEVELOPMENTS 446
15.5 FUJIFILM CORPORATION 447
15.5.1 COMPANY SNAPSHOT 447
15.5.2 REVENUE ANALYSIS 447
15.5.3 COMPANY SHARE ANALYSIS 448
15.5.4 PRODUCT PORTFOLIO 448
15.5.5 RECENT DEVELOPMENTS 448
15.6 AED.MD 450
15.6.1 COMPANY SNAPSHOT 450
15.6.2 PRODUCT PORTFOLIO 450
15.6.3 RECENT DEVELOPMENTS 450
15.7 ARQUER DIAGNOSTICS LTD 451
15.7.1 COMPANY SNAPSHOT 451
15.7.2 PRODUCT PORTFOLIO 451
15.7.3 RECENT DEVELOPMENTS 451

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.